|
1. Biologie
|
|
|
|
2.11 Etiologie - Alimentation
|
|
|
|
5.10 Traitements - Essais
|
|
|
|
5.12 Immunothérapies
|
|
|
|
5.2 Pharma
|
|
|
|
XBiotech Provides Update on Phase III COncology Study in Europe [XBiotech]
|
|
|
|
|
|
The
Company found 25 patients dropped off study prior to receiving any
dosing with drug or placebo. Analysis of patient blood samples also
revealed that 14 patients erroneously received either placebo or study
drug. In addition, 33 patients completed the study but failed to receive
scheduled DEXA scans, properly complete EORTC evaluation, or both. The
Company reports that these combined irregularities compromises data from
72 patients in the study.
|
|
|
|
|
|
|
5.2.2 Pharma - Fusions & Acquisitions
|
|
|
|
Pfizer-Allergan [In the Pipeline]
|
|
|
|
|
|
I
don’t think that the newly merged companies are going to purge the
R&D labs. They need them, still, and it’s not like Allergan’s
bringing much with them. But that doesn’t mean that things are
necessarily going to be great over there, either.
|
|
|
|
|
|
|
|
Merger Math: Is There Anything Left For Pfizer To Cut At Allergan? [Forbes]
|
|
|
|
|
|
There’s
simply not much to cut because those cuts were announced as part of
these other deals. (Pfizer, for its part, has cut 50,000 jobs over the
past five years.) This is also likely to irk those who are angry that
this deal will move Pfizer’s tax domicile to Ireland, cutting its tax
rate fro 25% to 18%.
|
|
|
|
|
|
|
5.3.4 Traitements - AMM (FDA, EMA)
|
|
|
|
|
|
|
|
|
6.10 Politiques
|
|
|